Meliam (Meloxicam)

Meloxicam selectively blocks the cyclooxygenase‑2 (COX‑2) enzyme, which is responsible for converting arachidonic acid into prostaglandins that drive inflammation, pain, and fever. By reducing prostaglandin production, meloxicam diminishes the inflammatory response while preserving COX‑1 activity that protects the stomach lining.

The appropriate dose of Meliam is determined by the prescribing healthcare professional based on the individual’s medical condition, severity of symptoms, age, renal function and other factors. Patients should follow the prescriber’s instructions and not adjust the dose without medical advice.

The safety of meloxicam in pregnancy and lactation has not been firmly established. It is generally advised to avoid use during the third trimester and to discuss potential risks with a healthcare provider before taking the medication while pregnant or breastfeeding.

To request Meliam, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Meliam (meloxicam) offers a relatively selective COX‑2 inhibition profile, which may provide comparable analgesic and anti‑inflammatory efficacy to non‑selective NSAIDs while potentially reducing gastrointestinal side effects. However, individual response varies, and clinicians consider patient risk factors, drug interactions and cost when selecting an NSAID.

Meliam should be stored at ambient temperature, below 25 °C (77 °F). Keep the tablets in the original packaging, protect them from moisture, heat and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Meliam is taken orally, usually with a full glass of water. It can be taken with or without food, but patients who experience stomach upset may find it helpful to ingest the tablet with meals. The exact administration schedule is set by the prescribing clinician.

Serious risks include gastrointestinal ulceration or bleeding, cardiovascular events such as heart attack or stroke, severe skin reactions (e.g., Stevens‑Johnson syndrome), and renal or hepatic impairment. Patients should be monitored for signs of these conditions and seek immediate medical attention if they occur.

Meliam is contraindicated in individuals with known hypersensitivity to meloxicam or other NSAIDs, those with active gastrointestinal bleeding or ulcer disease, patients with severe heart failure, and anyone who has experienced a serious allergic reaction to COX‑2 inhibitors. It should also be used with caution in patients with impaired kidney or liver function.